Historical Valuation
Amphastar Pharmaceuticals Inc (AMPH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.68 is considered Undervalued compared with the five-year average of 14.16. The fair price of Amphastar Pharmaceuticals Inc (AMPH) is between 34.34 to 60.77 according to relative valuation methord. Compared to the current price of 27.91 USD , Amphastar Pharmaceuticals Inc is Undervalued By 18.73%.
Relative Value
Fair Zone
34.34-60.77
Current Price：27.91
18.73%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Amphastar Pharmaceuticals Inc (AMPH) has a current Price-to-Book (P/B) ratio of 1.58. Compared to its 3-year average P/B ratio of 2.96 , the current P/B ratio is approximately -46.70% higher. Relative to its 5-year average P/B ratio of 2.86, the current P/B ratio is about -44.70% higher. Amphastar Pharmaceuticals Inc (AMPH) has a Forward Free Cash Flow (FCF) yield of approximately 9.31%. Compared to its 3-year average FCF yield of 7.45%, the current FCF yield is approximately 25.09% lower. Relative to its 5-year average FCF yield of 6.46% , the current FCF yield is about 44.12% lower.
P/B
Median3y
2.96
Median5y
2.86
FCF Yield
Median3y
7.45
Median5y
6.46
Competitors Valuation Multiple
AI Analysis for AMPH
The average P/S ratio for AMPH competitors is 2393.28, providing a benchmark for relative valuation. Amphastar Pharmaceuticals Inc Corp (AMPH.O) exhibits a P/S ratio of 1.68, which is -99.93% above the industry average. Given its robust revenue growth of 0.33%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for AMPH
1Y
3Y
5Y
Market capitalization of AMPH increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AMPH in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AMPH currently overvalued or undervalued?
Amphastar Pharmaceuticals Inc (AMPH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.68 is considered Undervalued compared with the five-year average of 14.16. The fair price of Amphastar Pharmaceuticals Inc (AMPH) is between 34.34 to 60.77 according to relative valuation methord. Compared to the current price of 27.91 USD , Amphastar Pharmaceuticals Inc is Undervalued By 18.73% .
What is Amphastar Pharmaceuticals Inc (AMPH) fair value?
AMPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Amphastar Pharmaceuticals Inc (AMPH) is between 34.34 to 60.77 according to relative valuation methord.
How does AMPH's valuation metrics compare to the industry average?
The average P/S ratio for AMPH's competitors is 2393.28, providing a benchmark for relative valuation. Amphastar Pharmaceuticals Inc Corp (AMPH) exhibits a P/S ratio of 1.68, which is -99.93% above the industry average. Given its robust revenue growth of 0.33%, this premium appears unsustainable.
What is the current P/B ratio for Amphastar Pharmaceuticals Inc (AMPH) as of Jan 09 2026?
As of Jan 09 2026, Amphastar Pharmaceuticals Inc (AMPH) has a P/B ratio of 1.58. This indicates that the market values AMPH at 1.58 times its book value.
What is the current FCF Yield for Amphastar Pharmaceuticals Inc (AMPH) as of Jan 09 2026?
As of Jan 09 2026, Amphastar Pharmaceuticals Inc (AMPH) has a FCF Yield of 9.31%. This means that for every dollar of Amphastar Pharmaceuticals Inc’s market capitalization, the company generates 9.31 cents in free cash flow.
What is the current Forward P/E ratio for Amphastar Pharmaceuticals Inc (AMPH) as of Jan 09 2026?
As of Jan 09 2026, Amphastar Pharmaceuticals Inc (AMPH) has a Forward P/E ratio of 7.68. This means the market is willing to pay $7.68 for every dollar of Amphastar Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Amphastar Pharmaceuticals Inc (AMPH) as of Jan 09 2026?
As of Jan 09 2026, Amphastar Pharmaceuticals Inc (AMPH) has a Forward P/S ratio of 1.68. This means the market is valuing AMPH at $1.68 for every dollar of expected revenue over the next 12 months.